132 related articles for article (PubMed ID: 37902999)
1. Clinical implication of genetic intratumor heterogeneity for targeted therapy in head and neck cancer.
Gram SB; Alosi D; Bagger FO; Østrup O; von Buchwald C; Friborg J; Wessel I; Vogelius IR; Rohrberg K; Rasmussen JH
Acta Oncol; 2023 Dec; 62(12):1831-1839. PubMed ID: 37902999
[TBL] [Abstract][Full Text] [Related]
2. Molecular Characterization of Locally Relapsed Head and Neck Cancer after Concomitant Chemoradiotherapy.
de Roest RH; Mes SW; Poell JB; Brink A; van de Wiel MA; Bloemena E; Thai E; Poli T; Leemans CR; Brakenhoff RH
Clin Cancer Res; 2019 Dec; 25(23):7256-7265. PubMed ID: 31439582
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive Genomic Profiling of Patient-matched Head and Neck Cancer Cells: A Preclinical Pipeline for Metastatic and Recurrent Disease.
Nisa L; Barras D; Medová M; Aebersold DM; Medo M; Poliaková M; Koch J; Bojaxhiu B; Eliçin O; Dettmer MS; Angelino P; Giger R; Borner U; Caversaccio MD; Carey TE; Ho L; McKee TA; Delorenzi M; Zimmer Y
Mol Cancer Res; 2018 Dec; 16(12):1912-1926. PubMed ID: 30108165
[TBL] [Abstract][Full Text] [Related]
4. Intratumor genetic heterogeneity and head and neck cancer relapse.
Pierik AS; Poell JB; Brink A; Stigter-van Walsum M; de Roest RH; Poli T; Yaromin A; Lambin P; Leemans CR; Brakenhoff RH
Radiother Oncol; 2024 Feb; 191():110087. PubMed ID: 38185257
[TBL] [Abstract][Full Text] [Related]
5. Is high-risk cutaneous squamous cell carcinoma of the head and neck a suitable candidate for current targeted therapies?
Zilberg C; Lee MW; Kraitsek S; Ashford B; Ranson M; Shannon K; Iyer NG; Ch'ng S; Low TH; Palme C; Clark J; Gupta R; Yu B
J Clin Pathol; 2020 Jan; 73(1):17-22. PubMed ID: 31300530
[TBL] [Abstract][Full Text] [Related]
6. The degree of intratumor mutational heterogeneity varies by primary tumor sub-site.
Ledgerwood LG; Kumar D; Eterovic AK; Wick J; Chen K; Zhao H; Tazi L; Manna P; Kerley S; Joshi R; Wang L; Chiosea SI; Garnett JD; Tsue TT; Chien J; Mills GB; Grandis JR; Thomas SM
Oncotarget; 2016 May; 7(19):27185-98. PubMed ID: 27034009
[TBL] [Abstract][Full Text] [Related]
7. Genetic landscape of metastatic and recurrent head and neck squamous cell carcinoma.
Hedberg ML; Goh G; Chiosea SI; Bauman JE; Freilino ML; Zeng Y; Wang L; Diergaarde BB; Gooding WE; Lui VW; Herbst RS; Lifton RP; Grandis JR
J Clin Invest; 2016 Jan; 126(1):169-80. PubMed ID: 26619122
[TBL] [Abstract][Full Text] [Related]
8. Whole exome sequencing uncovers HRAS mutations as potential mediators of resistance to metronomic chemotherapy.
Sambath J; Noronha V; Manda SS; Mishra R; Chandrani P; Patil V; Menon N; Chougule A; Ramachandran V; Limaye S; Kuriakose MA; Banavali SD; Kumar P; Prabhash K
Gene; 2024 Jan; 893():147952. PubMed ID: 37918550
[TBL] [Abstract][Full Text] [Related]
9. MATH, a novel measure of intratumor genetic heterogeneity, is high in poor-outcome classes of head and neck squamous cell carcinoma.
Mroz EA; Rocco JW
Oral Oncol; 2013 Mar; 49(3):211-5. PubMed ID: 23079694
[TBL] [Abstract][Full Text] [Related]
10. Intratumor heterogeneity is biomarker specific and challenges the association with heterogeneity in multimodal functional imaging in head and neck squamous cell carcinoma.
Rasmussen JH; Olin AB; Lelkaitis G; Hansen AE; Andersen FL; Johannesen HH; Kjaer A; Fischer BM; Specht L; Bentzen SM; von Buchwald C; Wessel I; Vogelius IR
Eur J Radiol; 2021 Jun; 139():109668. PubMed ID: 33848777
[TBL] [Abstract][Full Text] [Related]
11. Genomic Alterations in Head and Neck Squamous Cell Carcinoma: Level of Evidence According to ESMO Scale for Clinical Actionability of Molecular Targets (ESCAT).
Marret G; Bièche I; Dupain C; Borcoman E; du Rusquec P; Ricci F; Hescot S; Sablin MP; Tresca P; Bello D; Dubot C; Loirat D; Frelaut M; Lecerf C; Le Tourneau C; Kamal M
JCO Precis Oncol; 2021 Nov; 5():215-226. PubMed ID: 34994597
[TBL] [Abstract][Full Text] [Related]
12. Intratumor heterogeneity could inform the use and type of postoperative adjuvant therapy in patients with head and neck squamous cell carcinoma.
Mroz EA; Patel KB; Rocco JW
Cancer; 2020 Jan; 126(9):1895-1904. PubMed ID: 32083741
[TBL] [Abstract][Full Text] [Related]
13. Genomic Correlate of Exceptional Erlotinib Response in Head and Neck Squamous Cell Carcinoma.
Van Allen EM; Lui VW; Egloff AM; Goetz EM; Li H; Johnson JT; Duvvuri U; Bauman JE; Stransky N; Zeng Y; Gilbert BR; Pendleton KP; Wang L; Chiosea S; Sougnez C; Wagle N; Zhang F; Du Y; Close D; Johnston PA; McKenna A; Carter SL; Golub TR; Getz G; Mills GB; Garraway LA; Grandis JR
JAMA Oncol; 2015 May; 1(2):238-44. PubMed ID: 26181029
[TBL] [Abstract][Full Text] [Related]
14. Mutant p53 in head and neck squamous cell carcinoma: Molecular mechanism of gain‑of‑function and targeting therapy (Review).
Li M; Sun D; Song N; Chen X; Zhang X; Zheng W; Yu Y; Han C
Oncol Rep; 2023 Sep; 50(3):. PubMed ID: 37449494
[TBL] [Abstract][Full Text] [Related]
15. A phase II study of poziotinib in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.
Lee JH; Heo SG; Ahn BC; Hong MH; Cho BC; Lim SM; Kim HR
Cancer Med; 2021 Oct; 10(20):7012-7020. PubMed ID: 34528763
[TBL] [Abstract][Full Text] [Related]
16. DNA ploidy, proliferative capacity and intratumoral heterogeneity in primary and recurrent head and neck squamous cell carcinomas (HNSCC)--potential implications for clinical management and treatment decisions.
Hass HG; Schmidt A; Nehls O; Kaiser S
Oral Oncol; 2008 Jan; 44(1):78-85. PubMed ID: 17350326
[TBL] [Abstract][Full Text] [Related]
17. The Prognostic and Therapeutic Value of the Mutational Profile of Blood and Tumor Tissue in Head and Neck Squamous Cell Carcinoma.
Wilson HL; D'Agostino RB; Meegalla N; Petro R; Commander S; Topaloglu U; Zhang W; Porosnicu M
Oncologist; 2021 Feb; 26(2):e279-e289. PubMed ID: 33098199
[TBL] [Abstract][Full Text] [Related]
18. Therapy-Related Transcriptional Subtypes in Matched Primary and Recurrent Head and Neck Cancer.
Weber P; Künstner A; Hess J; Unger K; Marschner S; Idel C; Ribbat-Idel J; Baumeister P; Gires O; Walz C; Rietzler S; Valeanu L; Herkommer T; Kreutzer L; Klymenko O; Drexler G; Kirchner T; Maihöfer C; Ganswindt U; Walch A; Sterr M; Lickert H; Canis M; Rades D; Perner S; Berriel Diaz M; Herzig S; Lauber K; Wollenberg B; Busch H; Belka C; Zitzelsberger H
Clin Cancer Res; 2022 Mar; 28(5):1038-1052. PubMed ID: 34965946
[TBL] [Abstract][Full Text] [Related]
19. Current Trends in Precision Medicine and Next-Generation Sequencing in Head and Neck Cancer.
Solis RN; Silverman DA; Birkeland AC
Curr Treat Options Oncol; 2022 Feb; 23(2):254-267. PubMed ID: 35195839
[TBL] [Abstract][Full Text] [Related]
20. Identification of factors related to immunotherapy efficacy and prognosis in patients with advanced head and neck squamous cell carcinoma.
Xu X; Li R; Zhang L; Zhu G; Ren D; Wu L; Gong X
Diagn Pathol; 2021 Nov; 16(1):110. PubMed ID: 34823553
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
